daily californian logo

BERKELEY'S NEWS • NOVEMBER 20, 2022

Take a look at our 2022 midterm elections special issue!

Patent board announces interference between UC, Broad Institute CRISPR patents

article image

BARBARA RIES/UCSF | COURTESY

SUPPORT OUR NONPROFIT NEWSROOM

We're an independent student-run newspaper, and need your support to maintain our coverage.

|

Staff

JULY 15, 2019

The Patent Trial and Appeal Board, or PTAB, of the U.S. Patent and Trademark Office, or USPTO, announced an interference between multiple UC and multiple Broad Institute patents on June 25, a signal that the USPTO will resolve the seven-year ownership debate regarding CRISPR-Cas9 genome editing in eukaryotic cells.

On one side of this legal battle is UC and its collaborators, the University of Vienna in Austria and Emmanuelle Charpentier, director at the Max Planck Institute for Infection Biology in Berlin, Germany. On the other side is the Broad Institute, based in Cambridge, Massachusetts, and its collaborators, Harvard University and MIT, according to Barbara McClung, chief legal officer of Caribou Biosciences, a company that has an exclusive license to the CRISPR patent family from the UC and the University of Vienna.

According to a June 25 press release from the UC Office of the President, in September 2018, the U.S. Court of Appeals supported a PTAB judgement ruling that there was no interference between UC patent applications and Broad Institute patents, but this is no longer the case.

“The initiation of this interference proceeding highlights that previous decisions involving the Broad did not determine who was the first to invent this technology, and it lays out a pathway for resolving this important issue,” said Eldora Ellison, lead patent strategist on CRISPR matters for the UC and a director at the Sterne, Kessler, Goldstein & Fox law firm, in an email. “We are confident that the USPTO will ultimately recognize that the Doudna and Charpentier team hold the priority of invention specific to eukaryotic cells, as well as other settings covered by previous patents.”

According to McClung, the USPTO recognizes eukaryotic applications of CRISPR gene editing in Broad Institute patents as separate from CRISPR gene editing in any type of cell environment in UC patents.

McClung said she believes the UC applied for patent continuations for eukaryotic-specific methods to provoke the USPTO into declaring an interference with Broad Institute patents and that the UC is confident that it can win the interference in 2 1/2 to three years.

“Jennifer Doudna is one of the founders of Caribou Biosciences, so we believe the UC and their partners really invented CRISPR gene editing, so I’m looking forward to proving that,” McClung said.

Clarifications: A previous version of this article implied that Caribou Biosciences has an exclusive license to UC CRISPR patents. In fact, the company has an exclusive license to a CRISPR patent family from the UC and the University of Vienna.
Contact Yao Huang at [email protected] and follow him on Twitter at @Yhoneplus.
LAST UPDATED

JULY 23, 2019


Related Articles

featured article
British multinational corporation GlaxoSmithKline, or GSK, announced its partnership with UC Berkeley and UCSF on June 13 to build a state-of-the-art laboratory for CRISPR research, a revolutionary genetic modification technology.
British multinational corporation GlaxoSmithKline, or GSK, announced its partnership with UC Berkeley and UCSF on June 13 to build a state-of-the-art laboratory for CRISPR research, a revolutionary genetic modification technology.
featured article
featured article
Chinese scientist He Jiankui genetically mutated twins born last year to be resistant to HIV infection through the CRISPR-Cas9 gene-editing technology — however, according to an analysis released June 3 by UC Berkeley researchers, this mutation also comes with a 21 percent increase in mortality later in life.
Chinese scientist He Jiankui genetically mutated twins born last year to be resistant to HIV infection through the CRISPR-Cas9 gene-editing technology — however, according to an analysis released June 3 by UC Berkeley researchers, this mutation also comes with a 21 percent increase in mortality later in life.
featured article
featured article
The U.S. Patent and Trademark Office granted the University of California a new patent for the revolutionary CRISPR-Cas9 system of gene-editing technology on Tuesday. The patent, No. 10,301,651, covers methods of modulating DNA transcription.
The U.S. Patent and Trademark Office granted the University of California a new patent for the revolutionary CRISPR-Cas9 system of gene-editing technology on Tuesday. The patent, No. 10,301,651, covers methods of modulating DNA transcription.
featured article